Search results for "Normal"

showing 10 items of 2571 documents

Enzyme replacement and gene therapy for mucopolysaccharidoses: current progress and future directions

2015

Introduction: Mucopolysaccharidoses (MPS) are lysosomal storage disorders caused by the deficiency of enzymes that are responsible for the stepwise degradation of complex carbohydrates, the glycosaminoglycans. Whereas in the past the treatment of MPS consisted mainly of palliative care, enzyme replacement therapy (ERT) is now possible for some MPS disorders, and in the future many other therapeutic options will become available.Areas covered: This review, based on personal experience and the currently available literature, will give an overview on the efficacy and limitations of ERT and will discuss new therapeutic approaches, such as anti-inflammatory drugs, substrate reduction therapy, ch…

congenital hereditary and neonatal diseases and abnormalitiesPalliative carebusiness.industryHealth PolicyGenetic enhancementmedicine.medical_treatmentnutritional and metabolic diseasesLysosomal storage disordersHematopoietic stem cell transplantationEnzyme replacement therapyBioinformaticsImmunologymedicinePharmacology (medical)Substrate reduction therapybusinessPharmacology Toxicology and Pharmaceutics (miscellaneous)Expert Opinion on Orphan Drugs
researchProduct

GLI3 is rarely implicated in OFD syndromes with midline abnormalities

2011

A range of phenotypes including Greig cephalopolysyndactyly and Pallister-Hall syndromes (GCPS, PHS) are caused by pathogenic mutation of the GLI3 gene. To characterize the clinical variability of GLI3 mutations, we present a subset of a cohort of 174 probands referred for GLI3 analysis. Eighty-one probands with typical GCPS or PHS were previously reported, and we report the remaining ninety-three probands here. This includes nineteen probands (twelve mutations) who fulfilled clinical criteria for GCPS or PHS, forty-eight probands (sixteen mutations) with features of GCPS or PHS but who did not meet the clinical criteria (sub-GCPS and sub-PHS), twenty-one probands (six mutations) with featu…

congenital hereditary and neonatal diseases and abnormalitiesPallister-Hall SyndromeKruppel-Like Transcription FactorsNerve Tissue ProteinsBiologyBioinformaticsArticlePolydactylyMutationGLI3Mutation (genetic algorithm)GeneticsHumansAbnormalities MultipleSyndactylyGenetics (clinical)Human Mutation
researchProduct

Genetic features of neuroblastic tumors associated with opsoclonus-myoclonus syndrome opens up the possibility for detection in peripheral blood

2016

Opsoclonus–myoclonus syndrome (OMS) is a rare paraneoplastic, postinfectious, or parainfectious or idiopathic acute neurological syndrome in children and adults. OMS is characterized by involuntary...

congenital hereditary and neonatal diseases and abnormalitiesPathologymedicine.medical_specialtyGeneral NeuroscienceBiologymedicine.diseaseNeuroblastic TumorPeripheral bloodnervous system diseases03 medical and health sciences0302 clinical medicineCirculating tumor DNA030220 oncology & carcinogenesisOpsoclonus myoclonus syndromeImmunologymedicineNeurological syndromePharmacology (medical)Neurology (clinical)030217 neurology & neurosurgeryExpert Review of Neurotherapeutics
researchProduct

B and T lymphocytes are affected in lysosomal disorders--an immunoelectron microscopic study.

1991

Circulating lymphocytes of four patients with mucopolysaccharidoses II and IIIA, four patients with juvenile neuronal ceroid-lipofuscinosis, one patient each with glycogenosis type II, infantile neuronal ceroid-lipofuscinosis, and Gaucher disease were classified by immunoelectron microscopy as B or T lymphocytes. Disease-specific lysosomal inclusions as well as non-specific lysosomal organelles, especially Gall bodies were identified in B and T lymphocytes. These non-quantitative studies indicate that both B and T lymphocytes participate in the lysosomal storage process.

congenital hereditary and neonatal diseases and abnormalitiesPathologymedicine.medical_specialtyHistologyImmunoelectron microscopyMucopolysaccharidosisT-LymphocytesCentral nervous systemVacuoleBiologyPathology and Forensic MedicinePhysiology (medical)OrganellemedicineLysosomal storage diseaseHumansMicroscopy ImmunoelectronB-Lymphocytesnutritional and metabolic diseasesT lymphocytemedicine.diseasemedicine.anatomical_structureNeurologyNeuronal ceroid lipofuscinosisNeurology (clinical)Metabolism Inborn ErrorsNeuropathology and applied neurobiology
researchProduct

Expression of hMLH1 and hMSH2 proteins in ameloblastomas and tooth germs

2017

Background Mismatch repair proteins (MMRPs) are a group of nuclear enzymes that participate in the repair of base mismatches that occur during DNA replication in all proliferating cells. The most studied MMRPs are hMSH2 and hMLH1, which are known to be highly expressed in normal tissues. A loss of MMRPs leads to the accumulation of DNA replication errors in proliferating cells. Ki-67 is a biomarker regarded to be the gold-standard tool for determining cell proliferation by immunohistochemical methods. The aim of this study was to investigate the immunohistochemical expression of hMLH1, hMSH2 and Ki-67 proteins in ameloblastomas and tooth germs, to contribute to the understanding of the deve…

congenital hereditary and neonatal diseases and abnormalitiesPathologymedicine.medical_specialtyhMSH2hMLH1Ameloblastoma03 medical and health sciencesTooth germsGERMEN DENTARIO0302 clinical medicinemedicineHumansHOMOLOGO 1 DE LA PROTEINA MutL (1)AmeloblastomaGeneral DentistryTooth GermsOral Medicine and PathologyAmeloblastomasbiologyCell growthResearchDNA replicationTooth Germnutritional and metabolic diseases030206 dentistry:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseImmunohistochemistryJaw NeoplasmsANTIGENO Ki-67PROTEINA 2 HOMOLOGA a MutS (1)digestive system diseasesKi-67 AntigenMutS Homolog 2 ProteinAMELOBLASTOMAOtorhinolaryngology030220 oncology & carcinogenesisKi-67UNESCO::CIENCIAS MÉDICASbiology.proteinKi-67Biomarker (medicine)ImmunohistochemistrySurgeryDNA mismatch repairMutL Protein Homolog 1Medicina Oral Patología Oral y Cirugia Bucal
researchProduct

Lonoctocog alfa (rVIII-SingleChain) for the treatment of haemophilia A

2017

Introduction: The administration of factor VIII (FVIII) concentrates on-demand or on long-term prophylaxis is the effective and safe standard of care of patients with hemophilia A (HA). Development of neutralizing antibodies against exogenous FVIII and the short half-life of the current available products remain major challenges. There is currently a great interest towards newer FVIII products with the goal of reducing the inhibitor risk and increasing the half-life. Area covered: In this review, the authors describe the efficacy and safety of rVIII-SingleChain (Lonoctocog alfa), the first and only single chain recombinant FVIII (rFVIII) molecule developed for the prevention and treatment o…

congenital hereditary and neonatal diseases and abnormalitiesPediatricsmedicine.medical_specialtyHaemophiliaStandard of caresingle-chainHaemophilia AClinical BiochemistrySingle chain030204 cardiovascular system & hematologyHaemophiliaHemophilia A03 medical and health sciences0302 clinical medicineLONOCTOCOG ALFAhemic and lymphatic diseasesDrug DiscoverymedicineHumansPharmacologyClinical Trials as TopicFactor VIIIbusiness.industryCoagulantsDrug Discovery3003 Pharmaceutical ScienceRecombinant Proteinmedicine.diseaseRecombinant ProteinsCoagulantbusiness030215 immunologyHalf-LifeHuman
researchProduct

Audiological Findings in Children With Mucopolysaccharidoses Type I–IV

2017

Abstract Objective The aim of our study is to reflect hearing impairment of 23 children diagnosed with mucopolysaccharidosis (MPS) type I, II, III and IV. Methods Retrospective study of the clinical, audiological and treatment (medical vs surgical) findings of 23 children diagnosed with MPS type I, II, III and IV followed at a Tertiary Referral Hospital between 1997 and 2015. Results Six cases of MPS I, 8 of MPS II, 4 of MPS III and 5 of MPS IV were reviewed. 71.2% of patients had secretory otitis media (SOM) and 54% of patients had some type of hearing loss (HL). The behaviour of hearing loss was variable in each of the subgroups of MPS, finding greater involvement and variability in types…

congenital hereditary and neonatal diseases and abnormalitiesPediatricsmedicine.medical_specialtyHearing lossbusiness.industryMucopolysaccharidosisnutritional and metabolic diseasesRetrospective cohort studyGeneral MedicineAudiologyTertiary referral hospitalmedicine.disease03 medical and health sciences0302 clinical medicineOtitisQuality of lifemedicinemedicine.symptomskin and connective tissue diseases030223 otorhinolaryngologybusiness030217 neurology & neurosurgeryActa Otorrinolaringologica (English Edition)
researchProduct

BARDET-BIEDL SYNDROME – CASE PRESENTATION

2015

Bardet-Biedl syndrome (autosomal-recessive inheritance) is characterized by obesity, retinal dystrophy, polydactyly and mental retardation. The authors emphasize the necessary steps in order to establish the diagnosis for an infant with overweight, polydactyly and hypo-genitalism.

congenital hereditary and neonatal diseases and abnormalitiesPediatricsmedicine.medical_specialtyPolydactylyobesity (overweight)Retinal dystrophybusiness.industryRGeneral MedicineCase presentationpolydactylyOverweightmedicine.diseasePediatricsRJ1-570nervous system diseasesDevelopmental psychologyBardet–Biedl syndromemedicineMedicinemedicine.symptombusinessbardet-biedl syndromeRomanian Journal of Pediatrics
researchProduct

Pathogen safety of long-term treatments for bleeding disorders: still relevant to current practice

2013

Hemophilia defines a group of hereditary bleeding disorders: hemophilia A (deficiency of Factor VIII, FVIII), hemophilia B (deficiency of FIX), and para-hemophilia (deficiency of FV). These result from mutations in clotting factor genes. As in the large majority of bleeding disorders ([Table 1][1

congenital hereditary and neonatal diseases and abnormalitiesPediatricsmedicine.medical_specialtyTime FactorsLong term treatmentBlood transfusionmedicine.medical_treatmentTreatment outcomeEditorials and PerspectivesHemophilia AHemorrhagic DisordersHemorrhagic disorderhemic and lymphatic diseasesBlood-Borne PathogensmedicineHumansBlood TransfusionPathogenClotting factorbusiness.industryHematologyRecombinant ProteinsTreatment OutcomeCurrent practiceImmunologybusiness
researchProduct

Outcome of patients with classical infantile pompe disease receiving enzyme replacement therapy in Germany

2015

Enzyme replacement therapy (ERT) has been shown to improve outcome in classical infantile Pompe disease. The purpose of this study was to assess mortality, morbidity, and shortcomings of ERT in a larger cohort of patients treated outside clinical trials. To accomplish this, we retrospectively analyzed the data of all 23 subjects with classical infantile Pompe disease having started ERT in Germany between January 2003 and December 2010.Ten patients (43%) deceased and four others (17%) became ventilator dependent. Seven infants (30.5%) made no motor progress at all, while seven (30.5%) achieved free sitting, and nine (39%) gained free walking. Besides all the seven patients (100%) attaining n…

congenital hereditary and neonatal diseases and abnormalitiesPediatricsmedicine.medical_specialtybusiness.industryMEDLINEnutritional and metabolic diseases610 Medicine & healthDiseaseMetabolic myopathyEnzyme replacement therapymedicine.disease1301 Biochemistry Genetics and Molecular Biology (miscellaneous)ArticleClinical trial2712 Endocrinology Diabetes and Metabolism10036 Medical Clinic2724 Internal MedicineCohortmedicineGlycogen storage diseasebusiness
researchProduct